Vice President - Market Access & Pricing
$333k - $388k+ Equity component
Expert
Bachelor's, MBA, PharmD, PhD
San Carlos, CA, USA
HybridAt least three days per week on-site; relocation assistance is available.
Growth & Marketing
About the job
Requirements
- A bachelor's degree is required.
- At least 15 years of experience in market access, pricing, reimbursement, or related functions within biotech or pharma.
- Demonstrated experience supporting or leading product launches, ideally in vaccines, infectious disease, or buy-and-bill products.
- Strong understanding of adult vaccine access dynamics, including public health recommendations, Medicare Part B and Part D reimbursement, Medicaid, 340B program implications, CDC contract vehicles (Section 317 and VFC), and site-of-care economics.
- Experience operating in lean or pre-commercial biotech environments, with a demonstrated track record of building market access capabilities from the ground up.
- Ability to balance strategic thinking with hands-on execution.
- Strong cross-functional leadership and stakeholder influence skills.
- Experience managing gross-to-net financial modelling, including rebate strategy across payers.
- Ability to work collaboratively with HEOR teams to translate cost-effectiveness models, budget impact analyses, and payer value dossiers into P&T committee submissions or ICER reviews.
- Prior engagement with CDC immunization programs, state immunization programs, or ACIP-adjacent policy processes, and understanding of how ACIP recommendation language drives uptake across channels.
Responsibilities
- Lead development and execution of the U.S. market access strategy for the adult pneumococcal vaccine, including pricing, reimbursement, contracting, and channel strategy.
- Define and drive launch readiness plans aligned to regulatory approval and immunization guideline milestones, including ACIP or other recommending bodies.
- Shape access strategies across commercial payers, Medicare, Medicaid, and public health channels.
- Develop and execute engagement strategies for key stakeholders, including GPOs, IDNs, retail pharmacy, and public health entities.
- Establish pricing strategy and gross-to-net assumptions, ensuring alignment with vaccine-specific market dynamics.
- Ensure readiness for coding, coverage, reimbursement, and provider economics within buy-and-bill and pharmacy settings.
- Partner with Medical Affairs to define and deliver HEOR and value evidence to support payer and policy decision-making.
- Serve as the market access lead across cross-functional teams, aligning with Commercial, Medical, Regulatory, Government Affairs, and Finance.
- Build and lead a lean market access function, leveraging external partners to scale capabilities efficiently.
- Work cross-functionally to prepare for CDC immunization program, state immunization program, and ACIP-adjacent policy stakeholder engagements; translate ACIP recommendation language into access and coverage implications across all channels.
- Develop and execute integrated PBM, commercial payer, and Medicare Part B and D contracting strategies to ensure optimal formulary positioning, coverage, and patient access across channels.
- Support development of national retail pharmacy and alternate vaccination site strategies, establishing partnerships that maximize vaccine availability, administration, and uptake.
- Develop scenario-based access, reimbursement, and customer adoption strategies aligned to potential ACIP recommendation outcomes and evolving adult immunization guidelines.
Desired Qualifications
- An advanced degree such as an MBA, MPH, PharmD, or PhD.
- Product launch experience in vaccines, infectious disease, or buy-and-bill products.
About the company
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Carlos, California
Founded
2013
Get referred to Vaxcyte
See people who can refer or advise you
Simplify's Take
What believers are saying
- All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
- The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
- Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.
What critics are saying
- VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
- Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
- Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.
What makes Vaxcyte unique
- Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
- OPUS trials were finalized with FDA alignment for a planned BLA submission.
- Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Company Equity
- Stock Options
- Remote Work Options